141 related articles for article (PubMed ID: 16034302)
1. KIT receptor is expressed in more than 50% of early-stage malignant melanoma: a retrospective study of 261 patients.
Janku F; Novotny J; Julis I; Julisova I; Pecen L; Tomancova V; Kocmanova G; Krasna L; Krajsova I; Stork J; Petruzelka L
Melanoma Res; 2005 Aug; 15(4):251-6. PubMed ID: 16034302
[TBL] [Abstract][Full Text] [Related]
2. Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma.
Oba J; Nakahara T; Hayashida S; Kido M; Xie L; Takahara M; Uchi H; Miyazaki S; Abe T; Hagihara A; Moroi Y; Furue M
J Am Acad Dermatol; 2011 Dec; 65(6):1152-60. PubMed ID: 21700362
[TBL] [Abstract][Full Text] [Related]
3. c-Kit-dependent growth of uveal melanoma cells: a potential therapeutic target?
All-Ericsson C; Girnita L; Müller-Brunotte A; Brodin B; Seregard S; Ostman A; Larsson O
Invest Ophthalmol Vis Sci; 2004 Jul; 45(7):2075-82. PubMed ID: 15223779
[TBL] [Abstract][Full Text] [Related]
4. Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness.
Morton DL; Davtyan DG; Wanek LA; Foshag LJ; Cochran AJ
Cancer; 1993 Jun; 71(11):3737-43. PubMed ID: 8490924
[TBL] [Abstract][Full Text] [Related]
5. Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of Breslow thickness, ulceration and mitotic rate.
Svobodová S; Browning J; MacGregor D; Pollara G; Scolyer RA; Murali R; Thompson JF; Deb S; Azad A; Davis ID; Cebon JS
Eur J Cancer; 2011 Feb; 47(3):460-9. PubMed ID: 21115342
[TBL] [Abstract][Full Text] [Related]
6. Sentinel lymph node biopsy in thick malignant melanoma: a 10-year single unit experience.
Fairbairn NG; Orfaniotis G; Butterworth M
J Plast Reconstr Aesthet Surg; 2012 Oct; 65(10):1396-402. PubMed ID: 22552263
[TBL] [Abstract][Full Text] [Related]
7. Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma.
Piras F; Murtas D; Minerba L; Ugalde J; Floris C; Maxia C; Colombari R; Perra MT; Sirigu P
Histopathology; 2007 Jun; 50(7):835-42. PubMed ID: 17543072
[TBL] [Abstract][Full Text] [Related]
8. Metallothionein-overexpression as a prognostic factor for progression and survival in melanoma. A prospective study on 520 patients.
Weinlich G; Bitterlich W; Mayr V; Fritsch PO; Zelger B
Br J Dermatol; 2003 Sep; 149(3):535-41. PubMed ID: 14510986
[TBL] [Abstract][Full Text] [Related]
9. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision.
McKenna DB; Lee RJ; Prescott RJ; Doherty VR
Br J Dermatol; 2004 Mar; 150(3):523-30. PubMed ID: 15030337
[TBL] [Abstract][Full Text] [Related]
10. Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging.
Marghoob AA; Koenig K; Bittencourt FV; Kopf AW; Bart RS
Cancer; 2000 Feb; 88(3):589-95. PubMed ID: 10649252
[TBL] [Abstract][Full Text] [Related]
11. Histological expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) in human primary melanoma.
Bron LP; Scolyer RA; Thompson JF; Hersey P
Pathology; 2004 Dec; 36(6):561-5. PubMed ID: 15841691
[TBL] [Abstract][Full Text] [Related]
12. Soluble interleukin-2 receptor in stage I-III melanoma.
Ottaiano A; Leonardi E; Simeone E; Ascierto PA; Scala S; Calemma R; Bryce J; Caracò C; Satriano RA; Gianfranco N; Franco R; Botti G; Castello G
Cytokine; 2006 Feb; 33(3):150-5. PubMed ID: 16517174
[TBL] [Abstract][Full Text] [Related]
13. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.
Wagner JD; Ranieri J; Evdokimow DZ; Logan T; Chuang TY; Johnson CS; Jung SH; Wenck S; Coleman JJ
Plast Reconstr Surg; 2003 Aug; 112(2):486-97. PubMed ID: 12900606
[TBL] [Abstract][Full Text] [Related]
14. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors.
Monteagudo C; Martin JM; Jorda E; Llombart-Bosch A
J Clin Pathol; 2007 Jun; 60(6):596-9. PubMed ID: 16522748
[TBL] [Abstract][Full Text] [Related]
15. Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV.
Owen SA; Sanders LL; Edwards LJ; Seigler HF; Tyler DS; Grichnik JM
Cancer; 2001 Mar; 91(5):983-91. PubMed ID: 11251950
[TBL] [Abstract][Full Text] [Related]
16. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
Montone KT; van Belle P; Elenitsas R; Elder DE
Mod Pathol; 1997 Sep; 10(9):939-44. PubMed ID: 9310959
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in localized invasive cutaneous melanoma: high value of mitotic rate, vascular invasion and microscopic satellitosis.
Nagore E; Oliver V; Botella-Estrada R; Moreno-Picot S; Insa A; Fortea JM
Melanoma Res; 2005 Jun; 15(3):169-77. PubMed ID: 15917698
[TBL] [Abstract][Full Text] [Related]
18. [Survival analysis in patients with cutaneous malignant melanoma].
Radović-Kovacević V; Pekmezović T; Adanja B; Jarebinski M; Marinković J; Tomin R
Srp Arh Celok Lek; 1997; 125(5-6):132-7. PubMed ID: 9265233
[TBL] [Abstract][Full Text] [Related]
19. Melastatin expression and prognosis in cutaneous malignant melanoma.
Duncan LM; Deeds J; Cronin FE; Donovan M; Sober AJ; Kauffman M; McCarthy JJ
J Clin Oncol; 2001 Jan; 19(2):568-76. PubMed ID: 11208852
[TBL] [Abstract][Full Text] [Related]
20. Aquaporin 1 protein expression is associated with BRAF V600 mutation and adverse prognosis in cutaneous melanoma.
Imrédi E; Tóth B; Doma V; Barbai T; Rásó E; Kenessey I; Tímár J
Melanoma Res; 2016 Jun; 26(3):254-60. PubMed ID: 26848795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
